The Delayed Graft Function (DGF) drugs in development market research report provides comprehensive information on the therapeutics under development for Delayed Graft Function (DGF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Delayed Graft Function (DGF). Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Delayed Graft Function (DGF) and features dormant and discontinued products.

GlobalData tracks nine drugs in development for Delayed Graft Function (DGF) by eight companies/universities/institutes. The top development phase for Delayed Graft Function (DGF) is preclinical with five drugs in that stage. The Delayed Graft Function (DGF) pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Delayed Graft Function (DGF) pipeline products market are: Balmes Transplantation, Ischemix and Quark Pharmaceuticals.

The key targets in the Delayed Graft Function (DGF) pipeline products market include Cellular Tumor Antigen p53 (Tumor Suppressor p53 or Phosphoprotein p53 or Antigen NY CO 13 or TP53), Complement C2 (C3/C5 Convertase or C2 or EC 3.4.21.43), and Complement C1s Subcomponent (C1 Esterase or Complement Component 1 Subcomponent S or C1S or EC 3.4.21.42).

The key mechanisms of action in the Delayed Graft Function (DGF) pipeline product include Complement C1s Subcomponent (C1 Esterase or Complement Component 1 Subcomponent S or C1S or EC 3.4.21.42) Inhibitor with one drug in Phase II. The Delayed Graft Function (DGF) pipeline products include five routes of administration with the top ROA being Intravenous and six key molecule types in the Delayed Graft Function (DGF) pipeline products market including Small Molecule, and Antisense RNAi Oligonucleotide.

Delayed Graft Function (DGF) overview

Delayed graft function (DGF) is an indication of acute kidney injury (AKI) occurring after a kidney transplant, with attributes unique to the transplant process. AKI is defined as an increase in serum creatinine within 48 hours of an inciting event. In the case of a transplant, the timing is less straightforward. The diagnosis of DGF is complicated by a variety of definitions based on a range of clinical criteria dependent on the local transplant center, region, country. DGF is a major obstacle for allograft survival as it can be compounded by acute rejection and chronic allograft nephropathy.

For a complete picture of Delayed Graft Function (DGF)’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.